Concepedia

Glenn Van Aller

GV

6

Publications

243

Citations

6

H-Index

1991

Active since

Affiliations

Sterling Research Group (United States)(Current)

GlaxoSmithKline (United States)

Sterling Research Group

Glenn Van Aller is an author at Sterling Research Group (United States) specializing in medicine, drug discovery, and radiation oncology.

Top concepts

Publications per year

1991–2014

6

Publications

6

Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase

Jeffrey D. Carson, Glenn Van Aller, Ruth Lehr et al. · Biochemical Journal · 2007 · 118 citations

, , +12

Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia

Ryan G. Kruger, Helai P. Mohammad, Kimberly N. Smitheman et al. · Blood · 2013 · 30 citations

212 Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552

H. Mohammad, Kimberly N. Smitheman, Glenn Van Aller et al. · European Journal of Cancer · 2014 · 29 citations

, , +7

Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.

Paul J. Silver, Ronald L. Dundore, D C Bode et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 25 citations

Inhibition of low Km cGMP phosphodiesterases and Ca+(+)-regulated protein kinases and relationship to vasorelaxation by cicletanine.

Paul J. Silver, Brendan O’Connor, Wayne R. Cumiskey et al. · Journal of Pharmacology and Experimental Therapeutics · 1991 · 24 citations

Rows per page

1–5 of 6